Skip to main content
. Author manuscript; available in PMC: 2015 Oct 23.
Published in final edited form as: PET Clin. 2015 Jul 8;10(4):477–486. doi: 10.1016/j.cpet.2015.06.001

Table 1.

Type of intervention Pooled
number of
patients		 Number
of
studies		 Complete
remission
CR		 Partial
response
PR		 Minor
response
MR		 Stable
disease
SD		 Favourable
outcome
CR+PR+MR+SD		 Progressive
disease
PD		 Median
Progression
Free Survival
in months		 Toxicity
177Lu-DOTATATE 988 12 14 (1.4%) 310 (31.4%) 112 (11.3%) 390 (39.5%) 826 (83.6%) 162 (16.4%) 32

  • Nausea (29–35%)

  • Vomiting (10–18%)

  • Abdominal discomfort (6–11%)

  • Reversible hematotoxicity (5.9–22%)

  • Severe nephrotoxicity 1.3 %
Re-treatment with 177Lu-DOTATATE 88 3 3 (3.4%) 10 (11.4%) 7 (8%) 37 (42%) 57 (64.8%) 31 (35.2%) 18.5

  • Reversible hematotoxicity 21.2 %
Dual tx 90Y-DOTATATE + 177Lu-DOTATATE 88 2 2 (2%) 26 (30%) - 45 (51%) 73 (83%) 15 (17%) 18

  • Reversible hematotoxicity (7–15%)

  • G1 renal toxicity 12%
177Lu-DOTATATE combined with chemotherapy 86 2 6 (7%) 28 (32%) - 48 (56%) 82 (95%) 4 (5%) 39.5

  1. With Capecitabine

    • 1.1

      Transient hematoxicity G3/4 7%

    • 1.2

      Mild hand foot syndrome 9%

    • 1.3

      Thrombocytopenia G3 3%

  2. With Temozolomide+Capecitabine

    • 2.1

      Nausea 21%

    • 2.2

      Transient hematotoxicity G3/4 16.2 %

    • 2.3

      Neutropenia G3 6%

    • 2.4

      Thrombocytopenia G2 24%

    • 2.5

      MDS 3%

  3. With 5-FU

    • 3.1

      Thrombocytopenia G3/4 6%

    • 3.2

      Hepatotoxicity 11.5 %

    • 3.3

      Mean yearly reduction in GFR (with renal protection protocol) 2.2 ml/y